WELCH DANIEL G 4

What Happened

• Daniel G. Welch, a director of Prothena Corporation plc (PRTA), received a derivative award on 2026-05-15 covering 27,000 shares. The filing reports an acquisition price of $0.00 for the award (transaction code A — grant/award). This is a grant of an option/award, not an open-market buy or sale.

Key Details

• Transaction date: 2026-05-15; reported price: $0.00 (derivative award).
• Shares/units granted: 27,000.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting/exercisable terms (footnote): The option will vest and become exercisable for 100% of the shares on the earlier of the first anniversary of the grant date or the issuer’s 2027 annual general meeting, subject to continuous service as a director.
• Filing timeliness: Reported on 2026-05-15 for a transaction dated 2026-05-15 (appears timely).
• No 10b5-1 plan, tax-withholding, or immediate sale noted in this filing.

Context

• This was an equity award to a director (routine compensation), not an immediate purchase or sale of shares. The award vests in roughly one year and must be exercised to convert into common stock (per the footnote). Such grants are common for board compensation and do not by themselves indicate a buying or selling signal.